Cardiorenal actions of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog

Background The novel chimeric natriuretic peptide, CD-NP, is a Mayodesigned cGMP-activating synthetic peptide that consists of the 22-amino-acid (AA) residues of C-type natriuretic peptide (CNP) and the 15-AA C-terminal extension of Dendroaspis natriuretic peptide (DNP) [1]. The rationale for the design of CD-NP was to transform CNP, which activates natriuretic peptide receptor-B (NPR-B) and is natriuretic, diuretic and less hypotensive than ANP and BNP which activate NPR-A into a CNP-like peptide with added renal actions. The goal of this investigation was to directly compare the cardiorenal profile of CD-NP to that of CNP.